Skip to main content

Table 1 Summary of NS1 subunit vaccine applications in mouse models

From: Current progress in dengue vaccines

Approach DENV inoculation Mouse Outcome Reference
Monoclonal anti-NS1 Abs DENV2 (NGC) 100 IC50 i.c. BALB/c 50-93% Survival [135]
DNA vaccine: DENV2 (PL046) C3H/HeN pD2NS1: 50% Survival [136]
pD2NS1 107 PFU i. p. 50% Morbidity
pD2NS1 + pIL12 pD2NS1 + pIL12: 80% Survival
20% Morbidity
DNA vaccine: pcTPANS1 DENV2 (NGC) BALB/c 50% Survival [137]
4,32 log10PFU i.c.
DNA vaccine: pcTPANS1* DENV2 (NGC) BALB/c pcTPANS1: 96.7% Survival [138]
pcENS1** 4,32 log10PFU i.c. 10%Morbidity
pcEN1: 86.7% Survival
27% Morbidity
Vaccinia Virus: DENV4 (H241) BALB/c 67% Survival [139]
vNS1-15% NS2a 100IC50 i.c.
rNS1 + CFA (adjuvant) DENV2 (NGC) BALB/c 88% Survival [77]
Lethal dose i.c. 18% morbidity
rNS1 + LTG33D (adjuvant) DENV2 (NGC) BALB/c 50% Survival [140]
4,32 log10PFU i.c. 80% Morbidity
  1. *TPA human tissue plasminogen activator, a secretory signal sequence.
  2. **pcENS1: encoding the C-terminal E protein plus the NS1 region.
  3. i.c intracerebal, i.p intraperitoneal.